Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. 26381735 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Clinically, patients afflicted with ZM fusion harboring glioblastomas survived poorly relative to those afflicted with non-ZM-harboring sGBMs (P < 0.001). 25135958 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Of the five target genes that were enriched in the glioblastoma pathway, in the WikiPathway database, both HRas proto-oncogene, GTPase and MET proto-oncogene, receptor tyrosine kinase target genes of hsa-miR-139-5p, were found to be significantly associated with patient survival. 31423264 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE MET gain was detected in primary glioblastomas (47%) and secondary glioblastomas (44%), suggesting that this genetic alteration plays a role in the pathogenesis of both glioblastoma subtypes. 22672415 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease CTD_human Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. 22162573 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE In this study we investigated ALK, ROS1, and MET status in nine glioblastoma stem cell lines and tumors from which they arise. 28960893 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE This phenomenon is especially common among tumors with PDGFRA amplification: overall, 43% of PDGFRA-amplified GBM were found to have amplification of EGFR or the hepatocyte growth factor receptor gene (MET) as well. 22323597 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE MET and its ligand hepatocyte growth factor (HGF) play a critical role in the proliferation, survival, migration, invasion, angiogenesis, stem cell characteristics, and therapeutic resistance and recurrence of glioblastomas. 31221203 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE The oncogene MET was amplified in a glioblastoma which showed no EGFR gene amplification. 8017863 1994
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide. 24457079 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Intravenous administration of this formulation enhanced the curative efficacy of TMZ by downregulating the hepatocyte growth factor receptor (c-MET) gene in GBM U87 cells. 30982841 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE We investigated the effect of HGF/SF on matrix metalloproteinase-2 (MMP-2), membrane type 1 matrix metalloproteinase (MT1-MMP) and tissue inhibitors of metalloproteinases (TIMPs), expressions of c-Met/HGF receptor-positive human glioblastoma cells. 10389763 1999
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE We could also localize the MET amplicon to dmins in glioblastoma TX3095 by fluorescence in situ hybridization. 7534113 1995
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE We identified critical proteins that were altered in MET inhibitor-resistant GBM including mTOR, FGFR1, EGFR, STAT3, and COX-2. 30201763 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE We investigated the molecular factors and pathway activation signatures that determine sensitivity to c-MET inhibitors in a panel of glioblastoma and medulloblastoma cells, glioblastoma stem cells, and established cell line-derived xenografts using functional assays, reverse protein microarrays, and in vivo tumor volume measurements, but validation with animal survival analyses remains to be done. 23386689 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. 22020333 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Recurrence of GB after chemo-radiation could be associated with a variation in PlGF and MET expression. 27566180 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE GBM tissues frequently overexpressed MET protein at high levels compared with lower-grade gliomas. 28668888 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Our results indicated that the level of miR-562 was downregulated in GBM tissues and the expression of c-MET was upregulated in tumors. 30613151 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE In this study, we found that expression of the MET oncogene was associated with neurospheres expressing the gene signature of mesenchymal and proneural subtypes of glioblastoma. 22738909 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE PV-O glioblastomas were associated with lower expression of VEGFC (p = 0.032) than other periventricular locations, whereas MET overexpression remained exceptional. 26637806 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. 11238734 2001